US EditionImproved Retinal Drying and Treatment Durability In nAMD Qith Aflibercept 8mg
Summary by modernretina.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Improved Retinal Drying and Treatment Durability In nAMD Qith Aflibercept 8mg
Dilsher S. Dhoot, MD discusses how newer anti-VEGF treatments, particularly aflibercept 8mg, can provide improved anatomic outcomes and extended treatment intervals for patients with neovascular AMD who show persistent subretinal fluid despite treatment with first-generation agents.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage